Galindo GCG, Vega AMJ, Hernández MI, Ayala AR

Language: Spanish
References: 11
Page: 148-154
PDF size: 210.20 Kb.

ABSTRACT

Polycystic ovarian disease (PCOD) is the most important endocrine abnormality that affects women in reproductive age. It is characterized by chronic anovulation and hyperandrogenemia probably secondary to insulin resistance. Hence insulin sensitizers agents had been used in PCOD. Metformin is a biguanide used in the treatment of PCOD via decrease of hepatic gluconeogenesis and insulinemia; improvement peripheral glucose utilization, oxidative glucose metabolism, nonoxidative glucose metabolism and intracellular glucose transport. Such effects, when this drug is administered alone during 3 to 6 months, increase sex hormone binding globulin (SHBG), reduce free androgens index and hirsutism, decrease insulin resistance, and regulate menses in 60 to 70% of cases. Thiazolidinodiones are drugs that decrease insulin resistance in the liver with hepatic glucose production. Their mechanism of action is through the peroxisome proliferator-activated receptors γ (PPAR-γ), that help to decrease plasmatic concentrations of free fatty acids, pre and postprandial glucose, insulin, triglycerides, increased HDL cholesterol and decreased LDL, menses return to normality, with improvement of ovulation and decreased hirsutism. It seems that by modulation and attenuation of insulin resistance, hypoglucemic agents such as metfomin and thiazolidinodiones can be used effectively to treat anovulation, infertility and hyperandrogenemia.

REFERENCES

1. Azzis R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005;83(5):1343-6.

2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352(12):1223-36.

3. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 (alpha) activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23.

4. Hardman JG, Goodman GF, Limbird LE. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 2000;p:60.

5. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002;77(1):101-6.

6. Sahin Y, Yirmibes U, Kelestimur F, Aygen E. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004;113(2):214-20.

7. Akhil A, Pendergrass M, Granda R. Nonhypoglycemic effects of thiazolidinodiones. Ann Intern Med 2001;134:61-71.

8. De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633-67.

9. Romualdi D, Guido M, Ciampelli M, Giuliani M. Selective effects of pioglitazone on insulin and androgen abnormalities in normo and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210-8.

10. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005;90:60-65.

11. Ortiz D, Hernández I, Ayala A. Sensibilizantes de la insulina en el tratamiento del ovario poliquístico. Ginecol Obstet Mex 2005;73:315-27.